Combating Age-related Failure of Myelination in Multiple Sclerosis: An Exploratory Study (MAPMyeMS)
20. Juli 2026 aktualisiert von: Sarah Simmons, MD, PhD, University of Washington
Combating Age-related Failure of Myelination in Multiple Sclerosis: an Exploratory Study
This observational, longitudinal study will examine whether physical activity and other potentially modifiable lifestyle factors are associated with changes in myelin, the protective coating around nerve fibers, in older adults with multiple sclerosis (MS).
Participants will undergo magnetic resonance imaging (MRI) scans to measure myelin throughout the central nervous system and will wear wrist-worn activity trackers to assess physical activity over time.
Studienübersicht
Status
Noch keine Rekrutierung
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
The primary aim of this study is to explore clinical variables and potentially modifiable risk factors that are associated with improved myelination (both enhanced remyelination and reduced demyelination) in older adults living with multiple sclerosis. The emphasis here will be on discovery and generation of pilot data to support further definitive longitudinal observational studies, and ultimately, clinical trials on behavioral and/or pharmaceutical interventions to prevent demyelination and promote remyelination in people living with MS.
Participants will be categorized based on whether they meet or exceed the current physical activity guidelines of at least 150 minutes per week of moderate-intensity aerobic physical activity, 75 minutes per week of vigorous-intensity aerobic physical activity, or an equivalent combination.
At both baseline and 6 months, MRI and clinical assessments will be obtained, and chart review will be performed. Participants will wear a wrist-worn physical activity monitor and answer monthly questionnaires (assessed via REDCap survey) throughout the study period.
Linear regression will be performed to estimate the effect size of various physical activity variables (step count, sedentary time, and time spent in light/moderate/vigorous physical activity, aerobic capacity and overall strength) with 6-month change in myelination.
Studientyp
Beobachtungs
Einschreibung (Geschätzt)
14
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienkontakt
- Name: Susan R Robles, BS
- Telefonnummer: 206-598-0501
- E-Mail: msstudy@uw.edu
Studienorte
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten, 98133
- Multiple Sclerosis Center at UW Medical Center - Northwest
-
Kontakt:
- Susan R Robles, BS
- Telefonnummer: 206-598-0501
- E-Mail: msstudy@uw.edu
-
Hauptermittler:
- Sarah B Simmons, MD, PhD
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Nein
Probenahmeverfahren
Nicht-Wahrscheinlichkeitsprobe
Studienpopulation
Participants will include adults age 50-70 (inclusive) with a diagnosis of multiple sclerosis in the Greater Seattle area.
Beschreibung
Inclusion Criteria:
- Diagnosis of multiple sclerosis
- Independent with ambulation (able to walk 500m without aid)
- Disease duration >10 years
- Age 50 to 70 years (inclusive)
- Be able to read, speak, and understand English
Exclusion Criteria:
- Diagnosis of other neurologic disease that would interfere with interpretation such as stroke, myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), neuromyelitis optica (NMO), and sarcoidosis.
- Inability to complete study procedures (including obtaining MRI at BMIC and using Fitbit connected to smartphone)
- Currently participating in another clinical trial on remyelination
- Pregnancy. (Pregnancy status will be asked at screening and before each MRI. Pregnancy testing will not be offered as part of this study.)
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
|---|---|
|
Adults With Multiple Sclerosis
Participants with multiple sclerosis, age 50-70 (inclusive) will undergo quantitative MRI assessments, wearable activity monitoring, and questionnaire-based assessments over the study period.
|
No intervention is administered.
Participants undergo observational assessments including MRI, wearable activity monitoring, and questionnaires.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Quantitative MRI-derived myelin measure
Zeitfenster: Baseline and 6 months
|
Change in MRI-derived measures of myelin content within the central nervous system.
Specifically, the investigators will use macromolecular proton fraction (MPF), a quantitative MRI parameter which describes the magnetization transfer effect and defined as the relative amount of protons bound to biological macromolecules with restricted molecular motion.
|
Baseline and 6 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Total step count
Zeitfenster: Continuously collected during the 6-month study period
|
Total step count will measured using wrist-worn activity tracker.
|
Continuously collected during the 6-month study period
|
|
Self-reported physical activity
Zeitfenster: Baseline and monthly for the 6-month study period
|
Physical activity will be measured with the International Physical Activity Questionnaire-Short Form (IPAQ-SF).
This questionnaire will ask participants about their moderate and vigorous physical activity and time spent walking, to give a total sum score of Metabolic Equivalent of Task (MET).
Higher calculated (MET) scores indicate greater physical activity.
|
Baseline and monthly for the 6-month study period
|
|
Multiple Sclerosis Functional Composite (MSFC)
Zeitfenster: baseline and 6 months
|
The MSFC assesses walking function, hand function, and cognitive function and gives a composite score.
|
baseline and 6 months
|
|
Low Contrast Letter Acuity
Zeitfenster: Baseline and 6 months
|
The LCLA assesses visual function
|
Baseline and 6 months
|
|
Time spent in moderate-to-vigorous physical activity (MVPA)
Zeitfenster: Throughout the 6-month period
|
MVPA will be measured via wrist-worn physical activity monitor
|
Throughout the 6-month period
|
|
Sedentary Time
Zeitfenster: Throughout the 6-month period
|
Sedentary Time will be measured via wrist-worn fitness tracker
|
Throughout the 6-month period
|
|
Self-reported sedentary time
Zeitfenster: Baseline and monthly throughout the 6-month period
|
Self-reported sedentary time will be measured with the International Physical Activity Questionnaire-Short Form (IPAQ-SF).
This questionnaire will ask participants about their time spent sitting over the past 7 days, as an estimate of sedentary time.
|
Baseline and monthly throughout the 6-month period
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Physical Function
Zeitfenster: Baseline and 6 months
|
Physical function will be measured using the PROMIS Physical Function-MS 15a.
This self-report questionnaire assesses participants' physical functioning and ability to perform everyday activities.
|
Baseline and 6 months
|
|
Diet Quality
Zeitfenster: Baseline and monthly for the 6-month study period.
|
Diet will be measured using the Dietary Screener Questionnaire (DSQ), a self-report questionnaire that assesses the frequency of consumption of selected foods and beverages during the previous month to estimate intake of key dietary components, including fruits, vegetables, whole grains, dairy products, fiber, and added sugars.
The outcome measure will be the total DSQ-derived diet quality score.
|
Baseline and monthly for the 6-month study period.
|
|
Sleep Quality
Zeitfenster: Baseline and monthly for the 6-month study period.
|
Sleep quality will be measured with the Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance Short Form 8a, version 1.0.
Responses from each item will be summed to form a total raw score ranging from 8-40.
Higher scores indicate higher self-reported levels of sleep disturbance.
|
Baseline and monthly for the 6-month study period.
|
|
Stress
Zeitfenster: Baseline and monthly for the 6-month study period.
|
Stress will be measured using the Perceived Stress Scale, a 10-item self-report questionnaire that measures the degree to which situations in an individual's life are appraised as stressful during the previous month.
Higher scores indicate greater perceived stress.
Raw scores range from 0 to 40 and use reverse scoring for some items.
|
Baseline and monthly for the 6-month study period.
|
|
Depressive Symptom Severity
Zeitfenster: Baseline and monthly for the 6-month study period.
|
This outcome will be measured using the Patient Health Questionnaire- 8 (PHQ-8), a 8-item self-report measure that assesses the frequency and severity of depressive symptoms experienced during the previous 2 weeks.
Higher scores indicate greater depressive symptom burden.
|
Baseline and monthly for the 6-month study period.
|
|
Fatigue Severity
Zeitfenster: Baseline and monthly for the 6-month study period.
|
Fatigue will be measured using the Fatigue Severity Scale, a 9-item self-report questionnaire that evaluates the severity of fatigue and its impact on daily activities, work, family, and social functioning.
Higher scores indicate greater fatigue severity.
|
Baseline and monthly for the 6-month study period.
|
|
Alcohol Use
Zeitfenster: Baseline and monthly for the 6-month study period.
|
This will be measured via the Alcohol Use Disorders Identification Test - Consumption (AUDIT-C), a 3-item screening measure that assesses alcohol consumption patterns, including drinking frequency, quantity, and frequency of heavy drinking episodes.
Higher scores indicate greater alcohol use and risk for hazardous drinking.
|
Baseline and monthly for the 6-month study period.
|
|
Cannabis Use
Zeitfenster: Baseline and monthly for the 6-month study period.
|
This information will be collected through an adapted version of the Daily Sessions, Frequency, Age of Onset, and Quantity of Cannabis Use Inventory (DFAQ-CU), a self-report measure that assesses cannabis use history and patterns, including age of initiation, frequency of use, quantity consumed, and methods of administration.
|
Baseline and monthly for the 6-month study period.
|
|
Tobacco Use
Zeitfenster: Baseline and monthly for the 6-month study period.
|
This information will be collected through a self-developed questionnaire detailing self-reported tobacco and nicotine product use, including current use status, frequency of use, duration of use, and product type.
|
Baseline and monthly for the 6-month study period.
|
|
Comorbidity Burden
Zeitfenster: Baseline and 6 months
|
This information will be collected using a self-reported questionnaire of presence of physician-diagnosed medical and psychiatric comorbid conditions.
Comorbidity burden may be summarized as the total number of reported comorbidities.
|
Baseline and 6 months
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn (Geschätzt)
1. August 2026
Primärer Abschluss (Geschätzt)
1. Juni 2027
Studienabschluss (Geschätzt)
1. Juli 2027
Studienanmeldedaten
Zuerst eingereicht
15. Juli 2026
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
20. Juli 2026
Zuerst gepostet (Tatsächlich)
23. Juli 2026
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
23. Juli 2026
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
20. Juli 2026
Zuletzt verifiziert
1. Juli 2026
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- STUDY00025928
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
JA
Beschreibung des IPD-Plans
Study data may be shared in de-identified form with outside researchers and collaborators as requested and deemed acceptable by study investigators.
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- SAFT
- ICF
- ANALYTIC_CODE
- CSR
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Nein
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Nein
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .